What Fetus does

Fetus IVF, Inc. (operating as Fetus) is a private biotechnology company developing a non-invasive embryo selection system for in vitro fertilization (IVF) clinics. Founded in 2022 and headquartered in Praha, Czech Republic with a US corporate entity under the FABA group, the company uses a machine learning model trained on historical IVF outcomes to rank embryos by predicted viability based on standard, non-invasive lab observations captured during routine culture. The product consists of four integrated modules: an Input Module capturing standard lab observations, an Embryo Viability Prediction Model that estimates implantation probability, an Embryo Ranking Output that produces a ranked list for embryologist decision support, and a Clinical Workflow Integration layer that requires no changes to existing stimulation, retrieval, culture media, or vitrification protocols and no laser biopsy or extra disposables, plus an Embryologist Dashboard with audit trail.

The company's commercial mechanism is pre-revenue: it is in Phase 1 clinical development and operates through a pilot program with accredited IVF clinics globally, providing onboarding, a technical briefing, dashboard access, and dedicated support. Its intended go-to-market is enterprise/B2B field sales to IVF clinics as the primary customer segment, with downstream IVF patients as beneficiaries. Subscription-recurring revenue is the anticipated but undisclosed model.

Strategically, Fetus IVF holds pending patent filings on non-invasive embryo assessment workflows and predictive modeling and has secured Forbes and Czech/Slovak media coverage as a university-sourced biotech project. Its near-term milestones are to expand multi-center prospective studies and prepare a country-specific regulatory path; the company is also actively soliciting investors via a dedicated channel and has not yet disclosed pricing, funding amounts, or named clinic customers.

Name

Fetus

Legal name

Fetus IVF, Inc.

Website

https://fetus-ivf.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Fetus IVF, Inc. is a private biotechnology company developing a non-invasive, AI-driven embryo selection system that ranks IVF embryos by predicted viability from standard lab observations, serving accredited IVF clinics through a clinical pilot program under the FABA group.

Ownership category

akta.pro rank

Product category

AI-Assisted IVF Embryo Selection Software

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industry

Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC)

Keywords

• IVF embryo selection
• Embryo viability prediction
• Non-invasive fertility assessment
• AI-assisted reproduction
• Clinical decision support

Headquarters

HQ city

Praha

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Clinical Development / Pre-Revenue: Company is in Phase 1 clinical development. Not commercially available in all markets. Revenue model not yet disclosed as product is under clinical validation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Fetus IVF develops an AI/ML-based non-invasive embryo selection system for IVF clinics that analyzes standard laboratory observations and non-invasive readouts from routine embryo culture to rank embryos by likelihood of successful implantation. The system produces a ranked embryo list with audit trail and integrates with existing clinical workflows without requiring biopsies, laser procedures, or changes to stimulation, retrieval, culture media, or vitrification protocols. The product is currently in Phase 1 clinical development and not yet commercially available in all markets.

Product overview

Fetus IVF operates as a single unified product—a non-invasive embryo selection system for IVF clinics. The system consists of four integrated modules: an Input Module (captures standard lab observations and non-invasive readouts during routine culture), an Embryo Viability Prediction Model (trained on historical outcomes to estimate implantation probability), an Embryo Ranking Output (provides ranked list for embryologist decision support), and a Clinical Workflow Integration component (operates without changes to existing lab protocols). The company also offers a companion Embryologist Dashboard providing ranked embryo lists with audit trail. All components work together as a closed clinical decision support system currently in Phase 1 clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• Non-Invasive Embryo Selection System An AI/ML-based, non-invasive clinical decision support system that analyzes signals from a standard IVF workflow to rank embryos by likelihood of successful implantation, intended for embryologists and IVF clinics without requiring biopsies or changes to lab protocols.
• Input Module Captures standard lab observations and non-invasive readouts during routine IVF embryo culture to feed the prediction model.
• Embryo Viability Prediction Model Machine learning model trained on historical outcomes to estimate embryo viability probability as a surrogate for implantation and live birth outcomes.
• Embryo Ranking Output Provides a ranked list of embryos to assist embryologists in selecting which embryo to transfer first based on predicted viability.
• Clinical Workflow Integration Integration component that allows the system to operate without changes to stimulation, retrieval, culture media, or vitrification protocols and without laser biopsy or additional disposables.
• Embryologist Dashboard Dashboard providing a ranked embryo list and audit trail for clinical decision support during embryo selection at IVF clinics.

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

One partnership is on record.

• Accredited IVF ClinicscoreChannel Partner/ Reseller/ DistributorFetus partners with accredited IVF clinics that perform IVF treatments. The company does not offer treatments directly to patients. Partner clinics benefit from pilot participation with quick onboarding, minimal training, and a dashboard with ranked embryo list and audit trail. Clinics receive dedicated support and study toolkit.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Hamilton Thorne: Hamilton Thorne provides instruments, consumables, and software for the IVF and reproductive medicine markets, including laser systems used in embryo biopsy. It is a broad incumbent in ART lab technology with overlapping customer base in IVF clinics.
• Vitrolife: Vitrolife is a global IVF products and technology provider offering culture media, time-lapse systems, and other ART lab solutions. As an established IVF vendor with deep clinic relationships, it represents the incumbent workflow stack that Fetus would need to integrate with or displace.
• Genea Biomedx: Genea Biomedx develops and commercializes ART lab devices and software, including time-lapse incubation systems used for embryo assessment. Its presence in IVF clinics makes it a comparable technology provider and potential partner or competitor.
• Igenomix: Igenomix is a major reproductive genetics services provider offering PGT-A and related preimplantation genetic testing. It represents the incumbent invasive testing approach that Fetus's non-invasive model would compete against or complement.

Emerging players

• Genomic Prediction: Genomic Prediction offers advanced preimplantation genetic testing using whole-genome analysis for IVF embryo selection. It represents an alternative, genetics-driven embryo selection approach that competes for clinical adoption against non-invasive AI tools.
• LifeWhisper Diagnostics: LifeWhisper is an early-stage company developing AI-based non-invasive embryo assessment tools for IVF clinics. It targets the same non-invasive embryo selection use case as Fetus and serves as a relevant emerging competitor.
• TMRW Life Sciences: TMRW Life Sciences provides automated cryo-storage and digital chain-of-custody solutions for frozen eggs and embryos in IVF clinics. It serves the same IVF clinic customers and is part of the broader digital workflow infrastructure for ART.

Others

• Progyny: Progyny is a leading fertility benefits management company that contracts with employers and directs patients to IVF clinics. While not a technology competitor, it is a key demand-side player shaping how clinics adopt new embryo selection tools.

Direct peers

• Fairtility: Fairtility offers AI-based embryo quality assessment and selection tools for IVF clinics, including CHLOE, which ranks embryos using computer vision on time-lapse imagery. It competes head-on with Fetus in the non-invasive embryo ranking category.
• Alife Health: Alife Health is an AI-driven reproductive medicine company developing clinical decision support for IVF, including embryo selection and stimulation optimization. It directly overlaps with Fetus in applying machine learning to improve IVF outcomes for clinics and patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fetus